临床试验/CTIS2023-509969-20-00

CTIS2023-509969-20-00进行中（未招募）1 期

CC-90010-ST-001

Celgene Corp.0 个研究点目标入组 133 人开始时间: 2024年1月30日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Celgene Corp.
入组人数: 133

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

未提供

排除标准

未提供

研究者

发起方

相似试验

进行中（未招募）

A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapyextensive stage small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10041067Term: Small cell lung cancer Class: 100000004864

CTIS2023-509800-14-00Celgene Corp.66

进行中（未招募）

Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgerySubjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resectionMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864

CTIS2024-511171-15-00Celgene Corp.216

Trial to evaluate the administration of IDOR-1134-2831 vaccine in healthy participantsClostridioides difficile (C. difficile)MedDRA version: 20.0Level: PTClassification code: 10054236Term: Clostridium difficile infection Class: 100000004862

CTIS2023-506407-26-00Idorsia Pharmaceuticals Ltd.125

进行中（未招募）

A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular disease

CTIS2024-510878-24-00Cereno Scientific AB48

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid Tumors

CTIS2022-500849-24-00Tolremo Therapeutics AG25